Kineret is an injectable therapy approved for the treatment of signs and symptoms of rheumatoid arthritis (RA), in adults who have failed one or more disease modifying antirheumatic drugs (DMARDs). The drug is administered once-daily through subcutaneous injection.
RA is a disabling condition that causes pain, swelling and severe limitations of movement. Joint inflammation can destroy cartilage, tendons and ligaments, wear away bone and subsequently cause joint deformity. While RA can affect people at any age, it occurs most commonly in individuals ages 25 - 50.
The safety and efficacy of Kineret has been tested in almost 3,000 subjects. Four placebo-controlled trials evaluated Kineret in combination with other DMARDs or as a monotherapy. The drug was shown, both alone and in combination with other therapies, to improve the signs and symptoms of RA. Many clinical responses, including a decrease in inflammation and pain, were seen in the fourth treatment week and most were seen by week 12.
Adverse events associated with the use of Kineret may include (but are not limited to) the following:
Kineret (anakinra) is a direct and selective blocker of interleukin-1 (IL-1) that works by inhibiting the binding of IL-1 to the IL-1 receptor. IL-1 is a protein that occurs in excess in those with RA. IL-1 production is increased in response to the inflammatory stimuli present from RA.